Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection (Q40011360)

16 September 2017

Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection (English)

1 reference

16 September 2017

Mycobacterium ulcerans

0 references

9

Gisela Bretzel

1 reference

16 September 2017

8

Ohene Adjei

1 reference

16 September 2017

2

Ymkje Stienstra

1 reference

16 September 2017

Willemien A Nienhuis

1

1 reference

16 September 2017

K Mohammed Abass

3

1 reference

16 September 2017

Wilson Tuah

4

1 reference

16 September 2017

William A Thompson

5

1 reference

16 September 2017

Peter C Awuah

6

1 reference

16 September 2017

Nana Yaa Awuah-Boateng

7

1 reference

16 September 2017

Jan P Schouten

10

1 reference

16 September 2017

Tjip S van der Werf

11

1 reference

16 September 2017

language of work or name

English

0 references

publication date

7 December 2011

1 reference

Clinical Infectious Diseases

16 September 2017

1 reference

16 September 2017

54

1 reference

16 September 2017

4

1 reference

16 September 2017

519-526

1 reference

Mycobacterium ulcerans infection.

16 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Buruli ulcer: emerging from obscurity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Paradoxical Reaction during Tuberculosis Treatment in HIV-Seronegative Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Paradoxical expansion of intracranial tuberculomas during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Mycolactones and Mycobacterium ulcerans disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Chemistry of mycolactones, the causative toxins of Buruli ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

Pilot study of treatment of Buruli ulcer with rifampin and dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR856

21 January 2018

Identifiers

DOI

10.1093/CID/CIR856

1 reference

16 September 2017

1 reference